Penumbra (NYSE:PEN) announced today that it launched the Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) ...

Penumbra’s stock was up about 12% after the deal was announced Thursday morning.

Penumbra offers compelling growth in mechanical thrombectomy, with strong recent results and expanding addressable markets in pulmonary embolism and neurovascular. PEN’s STORM-PE and CLOSABLE studies ...

Penumbra (PEN) climbs on strong Q4 results and acquisition agreement with Boston Scientific (BSX), deal valued at $14.5B.

Boston Scientific Corp (NYSE:BSX) said on Thursday it has reached a deal to acquire medical technology firm Penumbra (NYSE:PEN) for about $14.5 billion, a move aimed at expanding its footprint in ...

Boston Scientific’s $374/share Penumbra deal boosts mechanical thrombectomy exposure and growth. Click here to learn more about BSX stock prospects.

Penumbra, Inc. (NYSE:PEN) ranks among the best medical device stocks to invest in. Needham raised Penumbra, Inc. (NYSE:PEN) from Hold to Buy on October 8 and set a $326 price target on the company’s ...